WEBSITE BSE:543271 NSE: JUBLINGREA Inc. Year: 2019 Industry: Chemicals My Bucket: Add Stock
Last updated: 15:54
Jubilant Ingrevia Ltd offers life science product and its solutions in India and across the world. It operates in 3 segments: Specialty Chemicals, Nutrition & Health Solutions, and Life Science Chemicals. The Speciality Chemicals section gives speciality substances, fine chemicals, crop safety chemical substances, and custom improvement and production services. The Nutrition & Health Solutions segment gives nutrients and fitness ingredients, animal nutrients and fitness solutions, and human nutrients and fitness solutions. The Life Science Chem...Read More
Jubilant Ingrevia Ltd offers life science product and its solutions in India and across the world. It operates in 3 segments: Specialty Chemicals, Nutrition & Health Solutions, and Life Science Chemicals. The Speciality Chemicals section gives speciality substances, fine chemicals, crop safety chemical substances, and custom improvement and production services. The Nutrition & Health Solutions segment gives nutrients and fitness ingredients, animal nutrients and fitness solutions, and human nutrients and fitness solutions. The Life Science Chemicals offers life science ingredients and ethanol. The business enterprise also offers pyridine and picolines, cyanopyridines, piperidines, acetyl pyridines, amino pyridines, halo pyridines, pyridine aldehydes, steel complexes, amino pyridines, halogenated pyridines, quaternary salts, alkyl pyridines, vitamin B3 and picolinates, riboflavin phosphate sodium, nutritional premixes, antioxidants, straight components, acetic anhydride, acetic acid, ethyl acetate, propionic anhydride, absolute alcohol, ethanol, biocompost, CO2 and ETO combinations. In addition, it gives direction design, method improvement, technique optimization, and scale-up and business manufacturing of intermediates. Further, the business enterprise gives nutrients, mineral premixes, stress regulator, amino acid, herbal choline, natural non-antibiotic boom promoter and egg pleasant enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. It serves pharmaceutical, nutrients, agrochemical, consumer, and business clients. The agency was formerly referred to as Jubilant LSI Ltd and changed its name to Jubilant Ingrevia Ltd in October 2020. Jubilant Ingrevia Ltd incorporated in 2019 and is based in Noida, India. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹10595 Cr.
Stock P/E 42.2
P/B 3.4
Current Price ₹665.2
Book Value ₹ 193.9
Face Value 1
52W High ₹851.9
Dividend Yield 0.75%
52W Low ₹ 535.3
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1020 | 966 | 1074 | 1024 | 1045 | 1057 | 1051 | 1038 | 1121 | 1051 |
| Other Income | 9 | 9 | 10 | 10 | 10 | 9 | 8 | 11 | 11 | 9 |
| Total Income | 1028 | 975 | 1084 | 1034 | 1056 | 1066 | 1060 | 1049 | 1132 | 1060 |
| Total Expenditure | 902 | 871 | 983 | 915 | 921 | 918 | 905 | 896 | 985 | 924 |
| Operating Profit | 126 | 104 | 101 | 119 | 135 | 148 | 155 | 153 | 146 | 136 |
| Interest | 13 | 15 | 14 | 14 | 15 | 12 | 14 | 13 | 12 | 12 |
| Depreciation | 34 | 34 | 36 | 39 | 40 | 40 | 39 | 41 | 41 | 45 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -13 |
| Profit Before Tax | 80 | 55 | 51 | 66 | 80 | 96 | 102 | 100 | 93 | 65 |
| Provision for Tax | 22 | 17 | 22 | 17 | 21 | 26 | 28 | 25 | 23 | 19 |
| Profit After Tax | 57 | 39 | 29 | 49 | 59 | 69 | 74 | 75 | 70 | 47 |
| Adjustments | 0 | 0 | -0 | 0 | -0 | 0 | 0 | -0 | -0 | -0 |
| Profit After Adjustments | 57 | 39 | 29 | 49 | 59 | 69 | 74 | 75 | 69 | 47 |
| Adjusted Earnings Per Share | 3.6 | 2.4 | 1.9 | 3.1 | 3.7 | 4.4 | 4.7 | 4.8 | 4.4 | 3 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 684 | 4949 | 4773 | 4136 | 4178 | 4261 |
| Other Income | 0 | 3 | 31 | 33 | 35 | 38 | 39 |
| Total Income | 0 | 687 | 4981 | 4806 | 4171 | 4215 | 4301 |
| Total Expenditure | 0 | 567 | 4118 | 4226 | 3715 | 3659 | 3710 |
| Operating Profit | -0 | 120 | 863 | 581 | 456 | 557 | 590 |
| Interest | 0 | 7 | 31 | 22 | 53 | 56 | 51 |
| Depreciation | 0 | 22 | 123 | 122 | 136 | 158 | 166 |
| Exceptional Income / Expenses | 0 | -13 | 0 | 0 | 0 | 0 | -13 |
| Profit Before Tax | -0 | 77 | 709 | 437 | 268 | 344 | 360 |
| Provision for Tax | 0 | 23 | 232 | 129 | 85 | 92 | 95 |
| Profit After Tax | -0 | 54 | 477 | 307 | 183 | 251 | 266 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -0 | 54 | 477 | 307 | 183 | 251 | 265 |
| Adjusted Earnings Per Share | -3.3 | 3.4 | 30 | 19.3 | 11.6 | 15.9 | 16.9 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 1% | -5% | 0% | 0% |
| Operating Profit CAGR | 22% | -14% | 0% | 0% |
| PAT CAGR | 37% | -19% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 0% | 17% | 16% | NA% |
| ROE Average | 9% | 9% | 11% | 9% |
| ROCE Average | 11% | 12% | 15% | 12% |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Shareholder's Funds | -0 | 1923 | 2433 | 2666 | 2737 | 2927 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 456 | 100 | 150 | 426 | 363 |
| Other Non-Current Liabilities | 0 | 93 | 197 | 253 | 270 | 324 |
| Total Current Liabilities | 0 | 894 | 1053 | 1180 | 1286 | 1401 |
| Total Liabilities | 0 | 3366 | 3782 | 4249 | 4719 | 5015 |
| Fixed Assets | 0 | 1805 | 1798 | 1846 | 2539 | 2581 |
| Other Non-Current Assets | 0 | 137 | 219 | 585 | 401 | 581 |
| Total Current Assets | 0 | 1424 | 1765 | 1818 | 1780 | 1853 |
| Total Assets | 0 | 3366 | 3782 | 4249 | 4719 | 5015 |
| #(Fig in Cr.) | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 73 | 38 | 73 | 79 |
| Cash Flow from Operating Activities | 0 | 112 | 453 | 462 | 430 | 508 |
| Cash Flow from Investing Activities | 0 | -44 | -72 | -472 | -569 | -393 |
| Cash Flow from Financing Activities | 0 | -72 | -418 | 42 | 144 | -129 |
| Net Cash Inflow / Outflow | 0 | -4 | -37 | 32 | 5 | -13 |
| Closing Cash & Cash Equivalent | 0 | 73 | 38 | 73 | 79 | 69 |
| # | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -3.32 | 3.41 | 29.99 | 19.34 | 11.58 | 15.88 |
| CEPS(Rs) | -3.32 | 4.8 | 37.75 | 27.03 | 20.19 | 25.85 |
| DPS(Rs) | 0 | 0.35 | 5 | 5 | 5 | 5 |
| Book NAV/Share(Rs) | -2.32 | 120.73 | 152.96 | 167.47 | 172.67 | 184.02 |
| Core EBITDA Margin(%) | 0 | 17.07 | 16.79 | 11.45 | 10.16 | 12.4 |
| EBIT Margin(%) | 0 | 12.35 | 14.93 | 9.59 | 7.73 | 9.53 |
| Pre Tax Margin(%) | 0 | 11.28 | 14.31 | 9.14 | 6.46 | 8.21 |
| PAT Margin (%) | 0 | 7.92 | 9.62 | 6.43 | 4.41 | 6 |
| Cash Profit Margin (%) | 0 | 11.14 | 12.11 | 8.99 | 7.7 | 9.76 |
| ROA(%) | -332 | 3.23 | 13.34 | 7.66 | 4.08 | 5.16 |
| ROE(%) | 0 | 5.65 | 21.89 | 12.07 | 6.79 | 8.91 |
| ROCE(%) | 0 | 6.86 | 28.84 | 16.01 | 9.8 | 11.16 |
| Receivable days | 0 | 250.55 | 38.75 | 41.69 | 47.67 | 51.39 |
| Inventory Days | 0 | 323.99 | 56 | 74.31 | 87.01 | 82.14 |
| Payable days | 0 | 342.47 | 95.87 | 113.03 | 133.54 | 136.97 |
| PER(x) | 0 | 76.51 | 15 | 18.6 | 39.02 | 40.91 |
| Price/Book(x) | 0 | 2.16 | 2.94 | 2.15 | 2.62 | 3.53 |
| Dividend Yield(%) | 0 | 0.13 | 1.11 | 1.39 | 1.11 | 0.77 |
| EV/Net Sales(x) | 0 | 6.71 | 1.48 | 1.26 | 1.88 | 2.62 |
| EV/Core EBITDA(x) | 0 | 38.32 | 8.49 | 10.39 | 17.07 | 19.63 |
| Net Sales Growth(%) | 0 | 0 | 623.45 | -3.57 | -13.34 | 1.01 |
| EBIT Growth(%) | 0 | 0 | 773.36 | -38.06 | -30.12 | 24.66 |
| PAT Growth(%) | 0 | 0 | 776.97 | -35.5 | -40.52 | 37.34 |
| EPS Growth(%) | 0 | 202.8 | 778.68 | -35.5 | -40.15 | 37.22 |
| Debt/Equity(x) | 0 | 0.28 | 0.09 | 0.15 | 0.27 | 0.26 |
| Current Ratio(x) | 0.3 | 1.59 | 1.68 | 1.54 | 1.38 | 1.32 |
| Quick Ratio(x) | 0.3 | 0.91 | 0.81 | 0.66 | 0.65 | 0.65 |
| Interest Cover(x) | 0 | 11.56 | 23.92 | 21.24 | 6.08 | 7.18 |
| Total Debt/Mcap(x) | 0 | 0.13 | 0.03 | 0.07 | 0.1 | 0.07 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 51.47 | 51.47 | 51.47 | 51.47 | 51.47 | 51.47 | 45.22 | 45.22 | 45.22 | 45.22 |
| FII | 6.35 | 6.58 | 6.55 | 7.22 | 6.89 | 7.12 | 6.96 | 5.96 | 6.15 | 6.49 |
| DII | 11.18 | 13.6 | 14.07 | 15.46 | 15.98 | 15.91 | 21.79 | 23.05 | 24.01 | 24.77 |
| Public | 30.99 | 28.34 | 27.9 | 25.85 | 25.65 | 25.5 | 26.02 | 25.76 | 24.62 | 23.51 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 8.2 | 8.2 | 8.2 | 8.2 | 8.2 | 8.2 | 7.2 | 7.2 | 7.2 | 7.2 |
| FII | 1.01 | 1.05 | 1.04 | 1.15 | 1.1 | 1.13 | 1.11 | 0.95 | 0.98 | 1.03 |
| DII | 1.78 | 2.17 | 2.24 | 2.46 | 2.55 | 2.53 | 3.47 | 3.67 | 3.82 | 3.95 |
| Public | 4.94 | 4.51 | 4.44 | 4.12 | 4.09 | 4.06 | 4.14 | 4.1 | 3.92 | 3.74 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15.93 | 15.93 | 15.93 | 15.93 | 15.93 | 15.93 | 15.93 | 15.93 | 15.93 | 15.93 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
